CARIPRAZINE

Information current as at: 1 October 2021

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Reagila®
Pharmaceutical company:
Seqirus (Australia) Pty Ltd
Condition/indication:
(therapeutic use)
  • Schizophrenia
PBAC Submission type:
New listing (Major submission)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
November 2020 PBAC meeting
Opportunity for consumer comment:
Open 26/08/2020 and close 07/10/2020 (see PBS Website)
PBAC meeting:
Held on 04/11/2020
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
07/12/2020
Lodgement of required documentation:
14/12/2020
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 24/12/2020
Status:
Finalised
Government processes:
Commenced on 20/04/2021
Medicine listed on the PBS:
01/09/2021 (see PBS schedule)

Case ID: a231

Page last updated: 30 September 2021

v0.9.15